Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “hold” rating reissued by investment analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports.
A number of other research analysts also recently weighed in on the company. UBS Group upped their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Royal Bank of Canada reiterated a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a report on Monday, February 3rd. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Bank of America reissued a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.83.
View Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Stock Up 0.7 %
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Sell-side analysts anticipate that Gilead Sciences will post 4.35 EPS for the current year.
Insider Buying and Selling at Gilead Sciences
In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
A number of institutional investors have recently bought and sold shares of GILD. nVerses Capital LLC bought a new position in Gilead Sciences in the 3rd quarter worth $25,000. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences during the fourth quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at about $29,000. 83.67% of the stock is owned by institutional investors.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Find and Profitably Trade Stocks at 52-Week Lows
- GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Fast and the Casual: Is Taco Bell Catching Up to Chipotle?
- Insider Trades May Not Tell You What You Think
- Broadcom Stock: Why the Upside Is Too Good to Ignore
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.